Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
BACKGROUND: In the UK, chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic cancer. Chemoradiotherapy is also an acceptable treatment option, for which gemcitabine, fluorouracil, or capecitabine can be used as concurrent chemotherapy agents. We aimed to...
Main Authors: | Mukherjee, S, Hurt, C, Bridgewater, J, Falk, S, Cummins, S, Wasan, H, Crosby, T, Jephcott, C, Roy, R, Radhakrishna, G, McDonald, A, Ray, R, Joseph, G, Staffurth, J, Abrams, R, Griffiths, G, Maughan, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2013
|
Similar Items
-
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer
by: Hurt, C, et al.
Published: (2017) -
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
by: Crosby, T, et al.
Published: (2013) -
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
by: Strauss, V, et al.
Published: (2019) -
SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
by: Virdee, P, et al.
Published: (2017) -
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
by: Mukherjee, S, et al.
Published: (2024)